July 17, 2014
1 min read

Nicox granted expanded North American marketing rights for Sjö

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Nicox S.A. has announced the acquisition of extended North American marketing rights for Sjö, an advanced diagnostic panel used for early detection of Sjögren’s syndrome.

Under the agreement with Immco Diagnostics, Nicox will be the sole promotional entity of Sjö to health care practitioners in North America; however, Immco will carry out the test in its Clinical Laboratory Improvement Amendments-approved laboratory in Buffalo, NY. Immco will also be responsible for regulatory activities and reimbursement, according to a press release.

A previous agreement between the two companies in June 2013 granted Nicox the rights to market Sjö to eye care specialists in the U.S., Canada, Mexico and Puerto Rico.

“Nicox has already started to impact the awareness of Sjögren’s syndrome among eye care specialists,” Bill Maggio, president and CEO of Immco Diagnostics, said in the release. “Broadening their reach to educate other medical specialties to adopt Sjö in their practices is a logical step and one which we believe will help to identify more patients who suffer from the serious effects of the disease but remain undiagnosed.”